扶正抗癌方治疗晚期非小细胞肺癌疗效的Meta分析

目的 探讨扶正抗癌方联合化疗治疗晚期非小细胞肺癌(NSCLC)的疗效和安全性.方法 在中国生物医学文献数据库、PubMed等数据库检索扶正抗癌方联合化疗治疗晚期NSCLC的随机对照试验(RCT),采用Meta分析专用软件RevMan 5.2进行系统评价.结果 共纳入6个RCT,均为B级文献,共有467例NSCLC患者.Meta分析显示,扶正抗癌方联合化疗治疗晚期NSCLC的有效率优于单纯化疗组,差异有统计学意义RR=1.87,95％ CI(1.28～2.72)];扶正抗癌方联合化疗组的不良反应发生率低于单纯化疗组,差异有统计学意义RR=0.29,95％ CI(0.16～0.54)].研究无明显发表偏倚.结论 现有研究表明,扶正抗癌方联合化疗治疗晚期NSCLC的有效率优于单纯化疗组,且安全性更佳.

A Meta-analysis of Efficacy of Fuzheng Kang'ai Formula for Advanced Non-small Cell Lung Cancer

Objective To study the efficacy and safety of Fuzheng Kang'ai formula combined with chemotherapy in treating advanced non-small cell lung cancer.Methods RCTs of Fuzheng Kang'ai formula combined with chemotherapy in treating patients with advanced non-small cell lung cancer were relieved from CMBdisc,PubMed database etc.RevMan 5.2 was adopted to carry out Meta analysis.Results A total of 6 RCTs with B-class and 467 NSCLC patients were enrolled.Meta analysis results showed the effective rate of Fuzheng Kang'ai formula combined with chemotherapy was superior to that of simple chemotherapy,with statistically significant difference RR =1.87,95 ％ CI (1.28 ～ 2.72)].And incidence rate of ADR of Fuzheng Kang'ai formula combined with chemotherapy was lower than that of simple chemotherapy,with difference being statistically significant RR =0.29,95％ CI (0.16 ～ 0.54)].The obvious publishing bias was not found.Conclusion Existing evidence showed that the effective rate of Fuzheng Kang'ai formula combined with chemotherapy is superior to simple chemotherapy,and the former has better safety.